Split–Combine Click-SELEX Reveals Ligands Recognizing the Transplant Rejection Biomarker CXCL9

• Published in: ACS chemical biology Vol. 17; no. 1; pp. 129 - 137
• Main Authors: Siegl, Julia, Nikolin, Christoph, Phung, Ngoc Linh, Thoms, Stefanie, Blume, Cornelia, Mayer, Günter
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 21.01.2022
• Subjects: Biomarkers - metabolism; Chemokine CXCL9 - chemistry; Click Chemistry; Graft Rejection - metabolism; Humans; Ligands; Protein Binding
• ISSN: 1554-8929; 1554-8937
• DOI: 10.1021/acschembio.1c00789

Renal rejection is a major incidence in patients after kidney transplantation and associated with allograft scarring and function loss, especially in antibody-mediated rejection. Regular clinical monitoring of kidney-transplanted patients is thus necessary, but measuring donor-specific antibodies is not always predictive, and graft biopsies are time-consuming and costly and may come up with a histological result unsuspicious for rejection. Therefore, a noninvasive diagnostic approach to estimate an increased probability of kidney graft rejection by measuring specific biomarkers is highly desired. The chemokine CXCL9 is described as an early indicator of rejection. In this work, we identified clickmers and an aptamer by split–combine click-SELEX (systematic evolution of ligands by exponential enrichment) that bind CXLC9 with high affinity. The aptamers recognize native CXCL9 and maintain binding properties under urine conditions. These features render the molecules as potential binding and detector probes for developing point-of-care devices, e.g., lateral flow assays, enabling the noninvasive monitoring of CXCL9 in renal allograft patients.